Full metadata record
DC FieldValueLanguage
dc.creatorRodríguez-Díaz, S. (Saray)-
dc.creatorCelay, J. (Jon)-
dc.creatorGoicoechea, I. (Ibai)-
dc.creatorJiménez, C. (Cristina)-
dc.creatorBotta, C. (Cirino)-
dc.creatorGarcía-Barchino, M.J. (María José)-
dc.creatorGarcés-Latre, J.J. (Juan José)-
dc.creatorLarrayoz, M. (Marta)-
dc.creatorSantos, S. (S.)-
dc.creatorAlignani, D. (Diego)-
dc.creatorVilas, A. (Amaia)-
dc.creatorPerez, C. (Cristina)-
dc.creatorGárate-Luzuriaga, S. (Sonia)-
dc.creatorSarvide, S. (Sarai)-
dc.creatorLópez-de-Arancibia, A. (Aitziber)-
dc.creatorReinhardt, H.C. (Hans Christian)-
dc.creatorCarrasco, Y.R. (Yolanda R.)-
dc.creatorSanchez-Garcia, I. (Isidro)-
dc.creatorLarrayoz, M.J. (María J.)-
dc.creatorCalasanz-Abinzano, M.J. (Maria Jose)-
dc.creatorPanizo, C. (Carlos)-
dc.creatorProsper-Cardoso, F. (Felipe)-
dc.creatorLamo-de-Espinosa-Vázquez-de-Sola, J.M. (José María)-
dc.creatorMotta, M. (Marina)-
dc.creatorTucci, A. (Alessandra)-
dc.creatorSacco, A. (Antonio)-
dc.creatorGentile, M. (Massimo)-
dc.creatorDuarte, S. (Sara)-
dc.creatorVitoria, H. (Helena)-
dc.creatorGeraldes, C. (Catarina)-
dc.creatorPaiva, A. (Artur)-
dc.creatorPuig, N. (Noemí)-
dc.creatorGarcía-Sanz, R. (Ramón)-
dc.creatorRoccaro, A.M. (Aldo M.)-
dc.creatorFuerte, G. (Gema)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.creatorMartinez-Climent, J.A. (José Ángel)-
dc.creatorPaiva, B. (Bruno)-
dc.date.accessioned2022-03-08T12:56:59Z-
dc.date.available2022-03-08T12:56:59Z-
dc.date.issued2022-
dc.identifier.citationRodríguez-Díaz, S. (Saray); Celay-Leoz, I. (Ion); Goicoechea-Oroz, I. (Ibai); et al. "Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma". Science Advances. 8 (3), 2022, eabl4644es
dc.identifier.issn2375-2548-
dc.identifier.other35044826-
dc.identifier.urihttps://hdl.handle.net/10171/63093-
dc.description.abstractNormal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the B lineage in elderly individuals and patients with lymphoplasmacytic lymphoma, a singular disease for studying lymphomagenesis because of the high prevalence of mutated MYD88. We observed similar accumulation of random mutations in B lineages from both cohorts and unexpectedly found MYD88(L265P) in normal precursor and mature B lymphocytes from patients with lymphoma. We uncovered genetic and transcriptional pathways driving malignant transformation and leveraged these to model lymphoplasmacytic lymphoma in mice, based on mutated MYD88 in B cell precursors and BCL2 overexpression. Thus, MYD88(L265P) is a preneoplastic event, which challenges the current understanding of lymphomagenesis and may have implications for early detection of B cell lymphomas.-
dc.description.sponsorshipThis study was supported by the International Waldenström’s Macroglobulinemia Foundation (Elting Family Research Fund). We also acknowledge grants from the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00489, and CB16/12/00284), the Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria co-financed by European Regional Development Fund-FEDER “A way to make Europe” (FIS nos. PI19/01451 and PI19/00818), the Spanish Association Against Cancer (AECC), the Fundacion Arnal Planelles, Cancer Research UK [C355/A26819] and FC AECC and AIRC under the Accelerator Award Program (EDITOR), the Research Fellow Award from the Multiple Myeloma Research Foundation, the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT, contract 680200), Associação Portuguesa Contra a Leucemia and Sociedade Portuguesa de Hematologia with financial support from Gilead Sciences and the Leukemia and Lymphoma Society, European Hematology Association, and Fondazione AIRC per la Ricerca sul Cancro (MFAG-18850). Medical editing support in the development of this manuscript, under the direction of the authors, was provided by S. Hill of Ashfield MedComms, an Ashfield Health company, funded by the Clinica Universidad de Navarra.-
dc.language.isoen-
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/680200/EU-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectLymphoplasmacytic lymphoma-
dc.subjectMutations-
dc.subjectMYD88-
dc.titlePreneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma-
dc.typeinfo:eu-repo/semantics/article-
dc.description.noteDistributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).-
dc.identifier.doi10.1126/sciadv.abl4644-
dadun.citation.number3-
dadun.citation.publicationNameScience Advances-
dadun.citation.startingPageeabl4644-
dadun.citation.volume8-

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
4.27 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.